This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Hapvida to participate in review of Gerdau-Unimed health insurance deal in Brazil

( January 29, 2024, 14:36 GMT | Official Statement) -- MLex Summary: Healthcare plan operator Hapvida will participate as an interested third party in the review of a deal involving steelmaker Gerdau Açominas and Unimed, Brazilian antitrust investigators said. In December, the Superintendence of the Administrative Council for Economic Defense, or CADE, temporarily allowed Hapvida to participate in the review, saying it could overturn its decision if Hapvida didn't provide the agency with pertinent information to prove its allegations about the deal. The Superintendence now said it is satisfied with the information provided by Hapvida. The transaction involves a planned investment by healthcare plan operator Unimed in Fundação Ouro Branco, which provides health services and is controlled by Gerdau. As an interested third party, Hapvida can assist CADE in its investigation.OJ statement and CADE decision follow in Portuguese....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login